Esra M. Cüce Aydoğmus, Günseli Ayşe İnhan Garip

Synergistic Effects of 4-Aminopyridine and Paclitaxel on MCF 7 Cell Line

Objectives: Aim of this study is to increase the effectiveness of paclitaxel (PTX) with the use of 4 - aminopyridine (4-AP) on breast cancer cell lineMCF-7.Methods: In this study, L-929 (ATCC CRL-6364) and MCF-7 (ATCC - HTB 22) cell lines were used. IC50 and survival values were determined bytrypan blue exclusion; cell cycle analysis was determined by measuring levels of Cdk2 and Histone (H3) and plasma membrane potential (Vm)measurements were performed using fluorescent Bis-(1,3-dibutylbarbituric acid) trimethine oxonol (DiBaC4(3)).Results: IC50 values were determined for two agents and these values were combined. Combination treatments ie. "4-AP (4 mM) + PTX (5 nM)"and "4-AP (4 mM) + PTX (7.5 nM)" decreased viability 17% ± 8.08 and 45% ± 3.18, respectively for L-929 cells and decreased viability 60%± 3.7 and74%± 2.6, respectively for MCF-7 cells. For L-929 cells, plasma membrane potential measurements resulted in depolarization for 4-AP, PTX (5 nM)and PTX (7.5 nM), and resulted in hyperpolarization for the combinations. For MCF-7 cells, plasma membrane potential measurements resulted indepolarization for 4-AP, PTX (7.5 nM) and 4-AP + PTX (5 nM), and resulted in hyperpolarization for PTX (5 nM) and 4-AP + PTX (7.5 nM). Changes ofCdk2 and H3 levels showed mostly G1 arrest for MCF 7 cells and G2/M arrest for L-929 cells.Conclusions: Combination treatments increased the cell death for MCF-7 cells. But, combination treatments didn't show synergistic effect on L-929which is accepted as a non-cancerous cell. These data showed that use of 4-AP in combination with the anticancer agent paclitaxel is a promisingapproach for cancer treatment.

PDF

___

[1] Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various Types and Management of Breast Cancer: an Overview. J Adv Pharm Technol Res 2010; 1(2): 109-126.
[2] Waks AG, W iner EP. Breast Cancer Treatment a Review. JAMA 2019; 321(3):288-300.
[3] Walsh V, Goodman J. The billion dollar molecule: Taxol in historical and theoretical perspective. Clio Med 2002; 66: 245 267.
[4] Erdemoğlu N, Şener B. Taksan Sınıfı Bileşiklerin Antitümör Etkileri. Ankara Ecz. Fak. Derg 2000; 29(1): 77-90 (Turkish)
[5] Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253-265.
[6] Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell 2014;25(18): 2677-2681.
[7] Bates E. Ion Channels in Development and Cancer. Annual Review of Cell and Developmental Biology 2015; 31(1): 231 247.
[8] Comes N, Serrano-Albarrás A, Capera J, Serrano-Novillo C, Condom E, Ramón y Cajal S, Ferreres JC, Felipe A. Involvement of potassium channels in the progression of cancer to a more malignant phenotype. Biochim. Biophys. Acta Biomembr. 2015; 1848: 2477-2492.
[9] Jensen JM, Shi R. Effects of 4-aminopyridine on stretched mammalian spinal cord: the role of potassium channels in axonal conduction. J Neurophysiol 2003 Oct; 90(4): 2334 2340.
[10] Wang W, Fan Y, Wang S, et al. Effects of voltage-gated K+ channel on cell proliferation in multiple myeloma. Scientific World Journal. 2014; 2014:785140. doi:10.1155/2014/785140
[11] Kim JA, Kang YS, Jung MW, Kang GH, Lee SH, Lee YS. Ca2+ influx mediates apoptosis induced by 4-aminopyridine, a K+ channel blocker, in HepG2 human hepatoblastoma cells. Pharmacology 2000 Feb; 60(2): 74-81.
[12] Wang W, Xiao J, Adachi M, Liu Z, Zhou J. 4-aminopyridine Induces Apoptosis of Human Acute Myeloid Leukemia Cells via Increasing [Ca2+] i Through P2 X7 Receptor Pathway. Cell Physiol Biochem 2011; 28: 199-208.
[13] Hu CL, Liu Z, Zeng XM, Liu ZQ, Chen XH, Zhang ZH, Mei YA. 4-Aminopyridine, a Kv channel antagonist, prevents apoptosis of rat cerebellar granule neurons. Neuropharmacology 2006; 51: 737-746.
[14] Barghouth PG, Thiruvalluvan M, Oviedo NJ. Bioelectrical regulation of cell cycle and the planarian model system. Biochimica et Biophysica Acta 2015;1848: 2629-2637.
[15] Sundelacruz S, Levin M, Kaplan DL. Role of Membrane Potential in the Regulation of Cell Proliferation and Differentiation. Stem Cell Rev 2009; 5(3): 231-46.
[16] Jordan MA, Wendell K, Gardiner S, Derry BW, Copp H, Wilson L. Mitotic Block Induced in HeLa Cells by Low Concentrations of Paclitaxel Results in Abnormal Mitotic Exit and Apoptotic Cell Death. Cancer Research 1996 ;56(15): 816-825.
[17] Gopalakrishnan M, Buckner SA, Whiteaker KL, Shieh CC, et al. (-) - (9S)-9-(3-Bromo-4-fluorophenyl)- 2,3,5,6,7,9-hexahydrothieno[3,2-b] quinolin-8(4H)-one 1,1-Dioxide(A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. I. In Vitro Characterization. The Journal of Pharmacology and Experimental Therapeutics 2002; 303:379 386.
[18] Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: A Review of Adverse Toxicity and Novel Delivery Strategies. Expert Opinion on Drug Safety 2007;6: 609-621.
[19] Ulukaya E, Ozdikicioglu F, Yilmaztepe Oral A, Demirci M. The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. Toxicology in Vitro 2008;22: 232-239.
[20]Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB. Cytotoxicity Studies of Paclitaxel (Taxol) in Human Tumor Cell Lines. Br. J. Cancer 1993; 68: 1104-1109.
[21] Ru Q, Tian X, Liu JS, Li CY. 4 - Aminopyridine inhibits Cell Proliferation and Affects Anti-Tumor Activities of Cell Cycle Specific Drugs. In: Chou JJ, Zhou H, editors. Proceedings of The 9TH International Conference on Bioinformatics and Biomedical Engineering; 2015 Sept 18-20; Shanghai, China. Taylor &Francis Group, UK: London. 2016; 383-408.
[22] Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel Resistance: Molecular Mechanisms and Pharmacologic Manipulation. Current Cancer Drug Targets 2003; 3: 1-19.
[23] Yardley DA. Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes. International Journal of Breast Cancer 2013;1: 1-15.
[24] Sinha D, Pascal HG, Khanna D, Khanna KK. Mitotic slippage: an old tale with a new twist. Cell Cycle 2019; 18:1: 7-15.
[25] Henriques AC, Ribeiro D, Pedrosa J, Sarmento B, Silva PMA, Bousbaa H. Mitosis inhibitors in anticancer therapy: when blocking the exit becomes a solution. Cancer Lett. 2019; 440: 64-68.
[26] Zasadil LM, Andersen KA, Yeum D, et al. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci Transl Med. 2014;6(229):229-243.
[27] Pushkarev VM, Starenki DV, Saenko VA, Yamashita S, Kovzun OI, Popadiuk ID, Pushkarev VV, Tronko MD. Effects of low and high concentrations of antitumour drug taxol in anaplastic thyroid cancer cells. Experimental Oncology 2009; 31:16-21.
[28]Huang X, Jan LY. Targeting potassium channels in cancer. J Cell Biol. 2014;206(2):151-162.